Anti-inflammatory  effects of seven  years treatment with  Omalizumab in  severe uncontrolled  asthmatics.
Pace
E
E
Istituto di Biomedicina e Immunologia Molecolare, Consiglio Nazionale delle Ricerche, Via Ugo La Malfa, 153, 90146 Palermo, Italy. pace@ibim.cnr.it
Ferraro
M
M
Bruno
A
A
Bousquet
J
J
Gjomarkaj
M
M
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism*; D015153:Blotting, Western; D002986:Clinical Trials as Topic; D017362:Cyclic AMP Response Element-Binding Protein / Q000187:drug effects; D005541:Forced Expiratory Volume; D051858:Forkhead Transcription Factors / Q000096:biosynthesis / Q000187:drug effects; D006801:Humans; D007150:Immunohistochemistry; D007249:Inflammation / Q000188:drug therapy; D016209:Interleukin-8 / Q000096:biosynthesis / Q000187:drug effects; D000069444:Omalizumab; D013995:Time
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017362:Cyclic AMP Response Element-Binding Protein; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D016209:Interleukin-8; D000069444:Omalizumab